In conversation with Cheryl Reicin

There’s no bigger booster of life sciences than Cheryl Reicin, who heads the group practice at Torys LLP.  American-born, she moved to Torys in 2004 from McDermott Will & Emery of New York, where she chaired an 85-attorney life sciences group, the largest in the U.S.  Her corporate and securities practice focuses on biotech, medical [...]

In conversation with Dr. Simon Pimstone

As CEO of Xenon Pharmaceuticals, Dr. Simon Pimstone and his partners have led the closely held Vancouver company on a journey of developing novel drugs that target genetically defined targets.  By studying genes responsible for rare and inherited diseases, Xenon figures they represent highly validated intervention points for new medicines.  In other words, going from [...]

In conversation with Dr. Erich Mohr

Dr. Erich Mohr enjoyed his time in academia as a neuropsychologist at the U.S. National Institutes of Health and University of Ottawa.  But he couldn’t resist the entrepreneurial call when it came knocking in 1996. Teaming up with a good friend, they formed CroMedia Global, a contract research organization that grew to 550 employees in [...]

Amgen gets rights to Array’s diabetes program

Array BioPharma has granted Amgen exclusive worldwide rights to its small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes. Under the accord, Array (NASDAQ:ARRY) will receive an upfront payment of $60 million (U.S.) and additional payments for certain clinical and commercial milestones, the [...]